Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Leukemia & Lymphoma|September 19, 2022
Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapyAlexandra Zduniak, Emilie Lévêque, Anne Perdrix, et al.
Diabetes, Obesity & Metabolism|October 1, 2024
Serum levels of the incretin-like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Results from the prospective pilot RFa-Ba-S studyHind Khiar, Emilie Lévêque, Antoine-Guy Lopez, et al.
Breast Cancer Research : BCR|May 30, 2020
Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancerFlorian Clatot, Anne Perdrix, Ludivine Beaussire, et al.
International Journal of Cancer|May 22, 2015
Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancerDavid Sefrioui, Anne Perdrix, Nasrin Sarafan-Vasseur, et al.
British Journal of Cancer|August 4, 2017
Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumoursDavid Sefrioui, France Blanchard, Emmanuel Toure, et al.
Oncotarget|November 2, 2016
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitorFlorian Clatot, Anne Perdrix, Laetitia Augusto, et al.
British Journal of Cancer|June 11, 2021
CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC)David Sefrioui, Ludivine Beaussire, André Gillibert, et al.
Pageof 3